Sign up to save your podcasts
Or
Share ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH 2025: Nurix CEO Arthur Sands discusses his company's BTK degrader data at ASH, and highlights the benefits of degraders more broadly in oncology and I&I
He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.
View all episodes
By BiotechTV
4.3
66 ratings
He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4.
More shows like BiotechTV - News
View all
We Study Billionaires - The Investor’s Podcast Network
3,374 Listeners
Bloomberg Businessweek
426 Listeners
WSJ Tech News Briefing
1,644 Listeners
The Meb Faber Show - Better Investing
938 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Readout Loud
321 Listeners
Value Investing with Legends
213 Listeners
Fiction - Comedy Fiction
6,444 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,855 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
5 Listeners
Cheeky Pint
49 Listeners